Smith 1985.

Methods	Trial design: RCT Trial grouping: parallel groups Ethics and informed consent: yes Follow‐up period: 24 weeks Sample size estimate: not stated ITT analysis: yes; number randomised: 258; number analysed: 258 Funding: grant from WB Pharmaceuticas
Participants	Inclusion criteria: people with intact skin Exclusion criteria: not stated Pretreatment age, mean: intervention: 82 years; control: 83 years gender, F/M: intervention: 104/25; control: 106/23 incontinent urine: intervention: 19%; control: 29% incontinent faeces: intervention: 29%; control: 42%
Interventions	Intervention group: Conotrane (silicone cream; 20% dimethicone 350; and a broad spectrum antiseptic (0.05% hydrargaphen)), skin washed, dried and ointment applied Control group: Unguentum cream, skin washed, dried and ointment applied
Outcomes	PU incidence Outcome type: dichotomous outcome Reporting: fully reported Unit of measure: numbers Direction: lower is better Data value: endpoint
Identification	Sponsorship source: WB Pharmaceuticals Country: UK Setting: long stay Comments: no comment Author's name: RG Smith Institution: Department of Geriatric Medicine Email: not stated Address: City Hospital, Greenbank Drive, Edingburgh, UK
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "The placebo ointment had been suitably scented so that it was indistinguishable from the active preparation"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No mention within the article; quote: "The placebo ointment had been suitably scented so that it was indistinguishable from the active preparation"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Results table 1: of 258 participants Data presented related to those who entered the study
Selective reporting (reporting bias)	Low risk	All outcomes reported in the paper were those outlined by the trial authors
Other bias	Unclear risk	One third more participants in the placebo group were incontinent of urine and one quarter more were incontinent of faeces when compared with the treatment group.